Bioxtal star-membrane laboratory research


Innovative Solutions for Receptor Activity Regulation

Theranyx is a French biotech company founded in 2010 on a unique technology platform that has proved instrumental in the development of novel therapeutic solutions for the treatment of cancer.

The mission of Theranyx is to discover, develop and commercialize new antibody fragments, mainly targeting cancers, with an improved efficiency and a lower toxicity than the compounds currently available to patients.

As a proof of concept, Theranyx discovered 12 fully functional antibodies fragments, demonstrating an innovative pharmaceutical profile against two ion channels and two peptides receptors, for which patent applications have been submitted.


Receptor                 Catalogue

Our new catalogue is now online. Please follow the link below to browse online, or download our PDF catalogue.
Read more

Membrane Protein X-ray Structure

As a fundamental aspect of computer-aided drug design, protein structure has become a standard tool of modern drug discovery process. Nevertheless membrane receptor structure resolution remains a challenging research project.
Read more

Membrane receptor purification

Our membrane receptor purification expertise has been built on more than a decade of technology development. We are today in the position to overcome all the major bottlenecks.
Read more

VHH, Camel antibody fragments

Image d'un VHH en 4 vue
VHHs also known as Therabodies are variable fragments of camelid single domain antibodies (sdAb). VHHs are obtained from PBMC of immunized llama or camel and offer superior properties than classical antibodies in many aspects
Read more